Navigation Links
TGen's Dr. Von Hoff wins award for cancer research

PHOENIX, Ariz. March 18, 2009 Dr. Daniel Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute (TGen), has won an award recognizing his achievements in cancer research.

Dr. Von Hoff, who also is Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare, will be recognized in the category of Health Care Research in a special report this month in Arizona Business Magazine. Dr. Von Hoff was honored March 4 at the magazine's 2009 Health Care Leadership Awards at the Ritz Carlton Phoenix.

This is the second major award in recent months for Dr. Von Hoff, a world-renowned cancer scientist and one of the leading experts in pancreatic cancer. In November, Dr. Von Hoff was named Arizona's Community Service Leader of the Year at the 2008 Governor's Celebration of Innovation, presented annually for contributions to Arizona's technology industry through relentless community involvement, leadership, visibility and excellence in economic development activity.

For more than 30 years, Dr. Von Hoff has dedicated his time and experience to the study of cancer and treatment methods. Arizona Business Magazine cited his:

  • International leadership in bringing to patients new anti-cancer agents many of which have been shown to increase patient survival.

  • Study of pancreatic and other forms of cancer.

  • Dedication to teaching.

  • Entrepreneurial research efforts, which have led to 12 patents.

Through the three-year-old partnership between TGen and Scottsdale Healthcare, Dr. Von Hoff leads a nearly 40-member staff in the research and treatment of cancer. TCRS at Scottsdale Healthcare is conducting 35 ongoing studies, involving the treatment of many patients with advanced cancer. The alliance works to identify new anti-cancer agents, and strives to bring diagnostic and treatment options to patients as fast as possible.

Dr. Von Hoff earned his medical degree from Columbia College of Physicians and Surgeons. He held an internship and residency at the University of California, San Francisco; conducted four years of cancer research at the National Cancer Institute; and worked as a faculty member at the University of Texas.

In Arizona, he has worked as Director of the Arizona Cancer Center in Tucson and as a Clinical Professor at the University of Arizona College of Medicine.

Dr. Von Hoff holds a presidential appointment to the National Cancer Advisory Board, is widely published and has been a keynote speaker at numerous national and international medical and scientific conferences.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. DOE awards UGA $3.1 million to support complex carbohydrate study nationwide
2. Lehigh researcher awarded $1.8 million NIH grant
3. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
4. Dr. King receives IADR Craniofacial Biology Research Award
5. Christopher McCulloch receives the IADR Research in Oral Biology Award
6. IADR Wilmer Souder Award presented to University of Colorado professor
7. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
8. Oxfords Dr. Rosalind Rickaby receives 2009 Rosenstiel Award
9. Sea Grant awards $820,000 for research under EPAs Long Island Sound study
10. NYU College of Dentistry awarded $1.9 million NIH grant for HIV research
11. Lincoln Park Zoo scientists awarded National Institutes of Health grant
Post Your Comments:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: